X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs LUPIN LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS LUPIN LTD NOVARTIS/
LUPIN LTD
 
P/E (TTM) x 321.8 28.2 1,139.0% View Chart
P/BV x 35.7 3.0 1,207.3% View Chart
Dividend Yield % 1.3 0.6 228.0%  

Financials

 NOVARTIS   LUPIN LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
LUPIN LTD
Mar-18
NOVARTIS/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs7581,465 51.7%   
Low Rs579727 79.6%   
Sales per share (Unadj.) Rs228.4349.6 65.3%  
Earnings per share (Unadj.) Rs31.75.6 571.0%  
Cash flow per share (Unadj.) Rs32.829.6 110.8%  
Dividends per share (Unadj.) Rs10.005.00 200.0%  
Dividend yield (eoy) %1.50.5 327.9%  
Book value per share (Unadj.) Rs297.1300.3 98.9%  
Shares outstanding (eoy) m24.69452.08 5.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x2.93.1 93.4%   
Avg P/E ratio x21.1197.2 10.7%  
P/CF ratio (eoy) x20.437.1 55.1%  
Price / Book Value ratio x2.23.6 61.6%  
Dividend payout %31.590.0 35.0%   
Avg Mkt Cap Rs m16,505495,502 3.3%   
No. of employees `0000.717.0 3.9%   
Total wages/salary Rs m1,44528,647 5.0%   
Avg. sales/employee Rs Th8,441.39,273.6 91.0%   
Avg. wages/employee Rs Th2,163.61,681.0 128.7%   
Avg. net profit/employee Rs Th1,173.1147.4 795.6%   
INCOME DATA
Net Sales Rs m5,639158,042 3.6%  
Other income Rs m1,7181,504 114.3%   
Total revenues Rs m7,357159,545 4.6%   
Gross profit Rs m-6331,475 -0.2%  
Depreciation Rs m2510,859 0.2%   
Interest Rs m552,044 2.7%   
Profit before tax Rs m1,57520,076 7.8%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m7922,885 27.4%   
Profit after tax Rs m7842,513 31.2%  
Gross profit margin %-1.119.9 -5.6%  
Effective tax rate %50.314.4 349.8%   
Net profit margin %13.91.6 874.1%  
BALANCE SHEET DATA
Current assets Rs m9,522122,095 7.8%   
Current liabilities Rs m3,29650,956 6.5%   
Net working cap to sales %110.445.0 245.3%  
Current ratio x2.92.4 120.6%  
Inventory Days Days3785 43.3%  
Debtors Days Days28120 23.7%  
Net fixed assets Rs m46129,876 0.0%   
Share capital Rs m123904 13.6%   
"Free" reserves Rs m7,213134,866 5.3%   
Net worth Rs m7,336135,771 5.4%   
Long term debt Rs m064,245 0.0%   
Total assets Rs m11,105263,054 4.2%  
Interest coverage x29.510.8 272.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.50.6 84.5%   
Return on assets %7.61.7 436.1%  
Return on equity %10.71.9 577.2%  
Return on capital %22.23.7 597.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6153,141 0.1%   
Fx outflow Rs m3,63019,335 18.8%   
Net fx Rs m-3,57033,807 -10.6%   
CASH FLOW
From Operations Rs m1,61017,512 9.2%  
From Investments Rs m687-14,073 -4.9%  
From Financial Activity Rs m-2,677-14,921 17.9%  
Net Cashflow Rs m-380-11,482 3.3%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 2.0 11.3 17.7%  
FIIs % 1.6 31.9 5.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.1 212.9%  
Shareholders   41,647 98,259 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUVEN LIFE  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ALEMBIC PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS